Compare Cytokinetics Inc (CYTK) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Extra Space Storage, Inc. — how do they compare? Cytokinetics Inc trades at $82.13 (market cap $11.12B), while Extra Space Storage, Inc. trades at $147.15 (market cap $30.74B). The key difference: Extra Space Storage, Inc. is far larger — about 2.8× Cytokinetics Inc's market cap, and Extra Space Storage, Inc. pays a 4.45% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | EXR | |
|---|---|---|
Market Cap | $11.12B | $30.74B |
Sector | Technology | Real Estate |
52-Week High | $87.26 | $152.75 |
52-Week Low | $33.23 | $126.67 |
Enterprise Value | $11.59B | $44.54B |
Dividend Yield | — | 4.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
EXR trades at $145.32, up 0.94% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating estimates at $1.14 versus $1.12 expected, maintaining a three-quarter beat streak. Revenue grew to $3.38B in 2025 with robust 70.63% gross margins. Analyst consensus is mixed with 12 Buy and 16 Hold ratings, targeting $155.88 average price. Recent $550 million debt issuance supports expansion amid steady operational cash flow of $1.85B.
Outlook remains stable with resilient self-storage demand offset by debt concerns. The 6.92% ROE and 32.66 P/E suggest fair valuation. Key risks include rising expenses and competitive supply pressures. Institutional sentiment leans cautious despite consistent dividend payments, with technical resistance near $146 limiting near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
